Literature DB >> 24643720

Underestimation of myelodysplastic syndrome incidence by cancer registries: Results from a population-based data linkage study.

Zoe K McQuilten1, Erica M Wood, Mark N Polizzotto, Lynda J Campbell, Meaghan Wall, David J Curtis, Helen Farrugia, John J McNeil, Vijaya Sundararajan.   

Abstract

BACKGROUND: Myelodysplastic syndromes (MDS) appear to be underreported to cancer registries, with important implications for cancer and transfusion support service planning and delivery. Two population-based databases were linked to estimate MDS incidence more accurately.
METHODS: Data from the statewide Victorian Cancer Registry (VCR) and Victorian Admitted Episode Dataset (VAED, capturing all inpatient admissions), in Australia, were linked. Incidence rates were calculated based on VCR reported cases and using additional MDS cases identified in VAED. Differences between reported and nonreported cases were assessed. A multivariate capture-recapture method was used to estimate missed cases.
RESULTS: Between 2003 and 2010, 2692 cases were reported to VCR and an additional 1562 cases were identified in VAED. Annual incidence rate for those aged 65 years and older based on VCR was 44 per 100,000 (95% confidence interval [CI] = 43-45 per 100,000) and 68 per 100,000 (95% CI = 67-70 per 100,000) using both data sets. Cases not reported to VCR were more likely to have had previous malignancies recorded in VAED (23% versus 19%, P = .003) and to require red cell transfusion (59% versus 54%, P = .003). Using the multivariate model, an estimated 1292 cases were missed by both data sources: the re-estimate was 5546 (95% CI = 5438-5655) MDS cases, with an annual incidence in those aged 65 or older of 103 per 100,000 (95% CI = 100-106).
CONCLUSIONS: This study reports a higher incidence of MDS using 2 data sources from a large and well-defined population than reported using cancer registry notifications alone.
© 2014 American Cancer Society.

Entities:  

Keywords:  cancer registries; incidence; myelodysplastic syndromes; secondary malignancies

Mesh:

Year:  2014        PMID: 24643720     DOI: 10.1002/cncr.28641

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

1.  Improved survival boosts the prevalence of chronic myeloid leukemia: predictions from a population-based study.

Authors:  Michael Lauseker; Roman Gerlach; Martin Tauscher; Joerg Hasford
Journal:  J Cancer Res Clin Oncol       Date:  2016-04-16       Impact factor: 4.553

2.  Comorbidities and malignancies negatively affect survival in myelodysplastic syndromes: a population-based study.

Authors:  Johanne Rozema; Mels Hoogendoorn; Robby Kibbelaar; Eva van den Berg; Nic Veeger; Eric van Roon
Journal:  Blood Adv       Date:  2021-03-09

3.  Factors associated with hematopoietic cell transplantation (HCT) among patients in a population-based study of myelodysplastic syndrome (MDS) in Minnesota.

Authors:  Angela R Smith; Erica D Warlick; Michelle A Roesler; Jenny N Poynter; Michaela Richardson; Phuong Nguyen; Adina Cioc; Betsy Hirsch; Julie A Ross
Journal:  Ann Hematol       Date:  2015-06-11       Impact factor: 3.673

Review 4.  Incidence and Burden of the Myelodysplastic Syndromes.

Authors:  Christopher R Cogle
Journal:  Curr Hematol Malig Rep       Date:  2015-09       Impact factor: 3.952

5.  A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry.

Authors:  Flavia Mayer; Laura Faglioni; Nera Agabiti; Susanna Fenu; Francesco Buccisano; Roberto Latagliata; Roberto Ricci; Maria Antonietta Aloe Spiriti; Caterina Tatarelli; Massimo Breccia; Giuseppe Cimino; Luana Fianchi; Marianna Criscuolo; Svitlana Gumenyuk; Stefano Mancini; Luca Maurillo; Carolina Nobile; Pasquale Niscola; Anna Lina Piccioni; Agostino Tafuri; Giulio Trapè; Alessandro Andriani; Paolo De Fabritiis; Maria Teresa Voso; Marina Davoli; Gina Zini
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-07-01       Impact factor: 2.576

Review 6.  Anemia in the Elderly.

Authors:  Domenico Girelli; Giacomo Marchi; Clara Camaschella
Journal:  Hemasphere       Date:  2018-04-17

7.  Incidence of myeloid neoplasms in Spain (2002-2013): a population-based study of the Spanish network of cancer registries.

Authors:  Marta Solans; Arantza Sanvisens; Alberto Ameijide; Susana Merino; Dolores Rojas; Araceli Alemán; Emilia Banqueri; Matilde Chico; Ana Isabel Marcos; Visitación de Castro; Leire Gil; Arantza López de Munain; Montse Puigdemont; Maria-José Sánchez; Josefina Perucha; Patricia Ruiz-Armengol; Mª Dolores Chirlaque; Marcela Guevara; Marià Carulla; Rafael Marcos-Gragera
Journal:  Sci Rep       Date:  2022-01-10       Impact factor: 4.379

8.  Myelodysplastic Syndrome/Acute Myeloid Leukemia Following the Use of Poly-ADP Ribose Polymerase (PARP) Inhibitors: A Real-World Analysis of Postmarketing Surveillance Data.

Authors:  Quanfeng Zhao; Pan Ma; Peishu Fu; Jiayu Wang; Kejing Wang; Lin Chen; Yang Yang
Journal:  Front Pharmacol       Date:  2022-06-15       Impact factor: 5.988

9.  Increased prescription rate of anti-infective agents after diagnosis of myelodysplastic syndromes.

Authors:  Johanne Rozema; Mels Hoogendoorn; Iris Potma; Inge Ten Seldam; Nic J G M Veeger; Robby E Kibbelaar; Arjan A van de Loosdrecht; Eric N van Roon
Journal:  EJHaem       Date:  2022-03-25

10.  Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK's population-based Haematological Malignancy Research Network 2004-15.

Authors:  Eve Roman; Alex Smith; Simon Appleton; Simon Crouch; Richard Kelly; Sally Kinsey; Catherine Cargo; Russell Patmore
Journal:  Cancer Epidemiol       Date:  2016-04-16       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.